Subjects with Molecularly Defined Familial Hypercholesterolemia or Familial Defective apoB-100 Are Not Being Adequately Treated
Open Access
- 18 February 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (2), e16721
- https://doi.org/10.1371/journal.pone.0016721
Abstract
To study whether subjects with a molecular genetic diagnosis of familial hypercholesterolemia (FH) or familial defective apoB-100 (FDB) are being adequately treated. A questionnaire regarding medical history was sent to 2611 subjects who had been provided with a molecular genetic diagnosis of FH or FDB, and a blood sample was obtained for lipid measurements. 956 (36.6%) of the 2611 subjects participated. The mean age for starting lipid-lowering therapy was 33.4 (±12.1) years. Among those below 18 years of age, only 20.4% were on lipid-lowering drugs, whereas 89.1% of those aged 18 and above were on lipid-lowering drugs. The mean levels of total serum cholesterol and LDL-cholesterol were 5.7 (±1.5) mmol/l and 3.9 (±1.3) mmol/l, respectively. Among those who were on lipid-lowering drugs, 29.0% and 12.2% had levels of LDL cholesterol below 3.0 mmol/l and 2.6 mmol/l, respectively. Only 47.3% of the 956 subjects were considered as being adequately treated largely due to a failure to titrate their drug regimens. From the use of cholesterol-years score, lipid-lowering therapy must start before the age of 20 in order to prevent the subjects from contracting premature coronary heart disease. The majority of FH/FDB subjects are being diagnosed late in life and are not being adequately treated. In order to prevent them from contracting premature coronary heart disease, it is key that levels of LDL cholesterol are normalized from a young age and that sufficient doses of lipid-lowering drugs are being used.This publication has 33 references indexed in Scilit:
- Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The NetherlandsAtherosclerosis, 2010
- Familial hypercholesterolaemia: summary of NICE guidanceBMJ, 2008
- Lipid Screening and Cardiovascular Health in ChildhoodPEDIATRICS, 2008
- Diagnosis of Familial Hypercholesterolemia in General Practice Using Clinical Diagnostic Criteria or Genetic Testing as Part of Cascade Genetic ScreeningPublic Health Genomics, 2008
- Screening for Lipid Disorders in Children: US Preventive Services Task Force Recommendation StatementPEDIATRICS, 2007
- Cascade genetic screening for familial hypercholesterolemiaClinical Genetics, 2004
- Follow up after a family based genetic screening programme for familial hypercholesterolaemia: is screening alone enough?BMJ, 2002
- Carotid intima-media thickness and plaque in patients with familial hypercholesterolaemia mutations and control subjectsEuropean Journal of Clinical Investigation, 1998
- Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group.BMJ, 1991
- The inheritance of hyperipoproteinaemia with xanthomatosis:A study of 132 kindredsClinical Genetics, 1976